Inventor · disambiguated record
Steven L. Warner
Also filed as: WARNER PH D STEVEN L · WARNER STEVEN L
36 granted patents·35 pending applications·313 citations·filing 2004–2024
97Inventor score
Files withSUMITOMO PHARMA ONCOLOGY INC19TOLERO PHARMACEUTICALS INC18SUMITOMO DAINIPPON PHARMA ONCOLOGY INC7UNIV ARIZONA7UNIV UTAH RES FOUND7
Top patents by PatentIndex Score
71 records- 0196US10835537B2Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Granted Nov 17, 2020·7 cites·6 claims
- 0296US10568887B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·10 cites·1 claims
- 0396US9901574B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·18 cites·12 claims
- 0495US10267787B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Apr 23, 2019·13 cites·13 claims
- 0595US8999988B2Protein kinase inhibitorsUNIV ARIZONA STATE·Filed 2013·Granted Apr 7, 2015·17 cites·12 claims
- 0694US10357488B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Jul 23, 2019·12 cites·8 claims
- 0794US7335662B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Feb 26, 2008·25 cites·10 claims
- 0894US7326713B2Substituted tricyclic compound as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Feb 5, 2008·26 cites·10 claims
- 0994US7312226B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Dec 25, 2007·26 cites·11 claims
- 1093US10132797B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·15 cites·15 claims
- 1193US8901120B2Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinaseBEARSS DAVID J·Filed 2012·Granted Dec 2, 2014·17 cites·31 claims
- 1292US10624880B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Apr 21, 2020·7 cites·16 claims
- 1392US10422788B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 24, 2019·11 cites·19 claims
- 1492US10202356B2JAK2 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2014·Granted Feb 12, 2019·12 cites·10 claims
- 1592US7326712B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2004·Granted Feb 5, 2008·39 cites·22 claims
- 1691US10682356B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·7 cites·1 claims
- 1790US11497756B2Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidibSUMITOMO PHARMA ONCOLOGY INC·Filed 2018·Granted Nov 15, 2022·4 cites·18 claims
- 1890US9493454B2Multiple kinase pathway inhibitorsMANNKIND CORP·Filed 2013·Granted Nov 15, 2016·13 cites·24 claims
- 1988US9714247B2Multiple kinase pathway inhibitorsMANNKIND CORP·Filed 2016·Granted Jul 25, 2017·6 cites·10 claims
- 2087US8703767B2Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsBEARSS DAVID J·Filed 2012·Granted Apr 22, 2014·10 cites·18 claims
- 2184US9206176B2Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsUNIV UTAH RES FOUND·Filed 2014·Granted Dec 8, 2015·6 cites·18 claims
- 2283US10752594B2JAK1 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Aug 25, 2020·1 cites·11 claims
- 2383US8552018B2Substituted tricyclic compounds as protein kinase inhibitorsHURLEY LAURENCE H·Filed 2011·Granted Oct 8, 2013·7 cites·7 claims
- 2482US2024173319A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2580US2023390288A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2679US2024083855A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO PHARMA AMERICA INC·Filed 2023·Application pending·0 cites
- 2777US2023181586A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2876US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 2975US8987335B2Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitorsVANKAYALAPATI HARIPRASAD·Filed 2012·Granted Mar 24, 2015·1 cites·8 claims
- 3074US2024075033A1Alk5 inhibitors for treating myelodysplastic syndromeSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 3172US2025082634A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 3272US2020200737A1Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3371US9828376B2Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsUNIV UTAH RES FOUND·Filed 2013·Granted Nov 28, 2017·1 cites·14 claims
- 3471US9266838B2Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitorsVANKAYALAPATI HARIPRASAD·Filed 2013·Granted Feb 23, 2016·1 cites·8 claims
- 3571US2021052568A1Predicting response to alvocidib by mitochondrial profilingSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 3669US2021070715A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 3768US2023000864A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 3868US2023165857A1Axl kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3968US2023233557A1Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 4068US2021228582A1Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 4166US2020276174A1Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4263US11471456B2Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 18, 2022·0 cites·23 claims
- 4363US2019314357A1Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4462US11400091B2AXL kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 2, 2022·0 cites·36 claims
- 4562US2009099165A1Protein Kinase InhibitorsUNIV ARIZONA·Filed 2007·Application pending·0 cites
- 4661US2021113562A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 4761US2024360135A1Imidazo[1,2-b]pyridazinyl compounds and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 4861US2022339172A1Methods for treating castration-resistant and castration-sensitive prostate cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 4958US11712433B2Compositions comprising PKM2 modulators and methods of treatment using the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 1, 2023·0 cites·19 claims
- 5058US2024197729A1ALK-5 Inhibitors and Uses ThereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Steven L. Warner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →